Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

to placebo or teriflunomide, 7mg or 14mg, once daily. The primary endpoint was annualized relapse rate defined as the number of confirmed relapses per patients-year. The key secondary endpoint was the time to disability progression measured by EDSS. Safety and tolerability evaluations were based on treatment emergent adverse events, physical examinations, vital signs and laboratory investigations.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, unpredictable and progressively disabling disease. Patients with MS typically are diagnosed at a young age and they face a lifetime of uncertainty with gradually declining health. Today, over two million people around the world suffer from MS. MS is the result of damage to myelin, a protective sheath surrounding nerve fibres of the central nervous system. When myelin is damaged, this interferes with messages between the brain and other parts of the body. Multiple sclerosis is a very variable condition and the symptoms depend on which areas of the central nervous system have been affected. There is no definite pattern to MS and everyone with MS has a different set of symptoms, which vary from time to time and can change in severity and duration, even in the same person. Management of MS is complex; early intervention in the pathological process is recommended in order to delay disease progression or at least, slow it down. A complex support system is required for the care of MS patients, including health and social services, as well as various healthcare professionals. Although there is no known cure for multiple sclerosis, several therapies are proven to be helpful but there remains an unmet need for new oral therapies with an acceptable benefit/risk profile.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 19, 2014 The “Human Insulin ... Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, ... NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018” ... restraints, challenges, opportunities, current market trends, and strategies ... the estimates and forecasts of the revenue and ...
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific hardware ... market in Asia-Pacific with analysis and forecast of revenue. ... is expected to reach $51,362.6 million by 2018, at ... Browse through the TOC of the Asia-Pacific hardware encryption ... analysis provided. This also provides a glimpse of the ...
(Date:10/18/2014)... According to a new market research report ... Global Trends & Forecasts up till 2017”, hydraulic fracturing ... This value is expected to increase from $40 billion ... CAGR during the same period. North America is expected ... terms of hydraulic horse power supplied by the year ...
(Date:10/17/2014)... journey through the looking-glass to Wonderland, mirrors in the ... ways, including a new class of mirror that works ... The Optical Society,s (OSA) new high-impact journal ... time, a new type of mirror that forgoes a ... by using an unusual magnetic property of a non-metallic ...
Breaking Biology Technology:Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4
... April 4 /PRNewswire-FirstCall/ - ProMetic Life Sciences ... Rohwer, Pathogen,Removal and Diagnostics Technology Inc.,s ("PRDT") ... Research Scientist will present at,the American Chemical ... from April 6 - 10, 2008. Drs ...
... /Xinhua-PRNewswire-FirstCall/ -- WuXi,PharmaTech (Cayman) Inc. (NYSE: ... and medical device research and development,outsourcing company ... States, today,announced that it has filed a ... and Exchange Commission for a proposed follow-on ...
... FRANCISCO, Calif., and SINGAPORE, April 4, 2008 /PRNewswire/,-- ... on the,discovery and development of monoclonal antibody therapeutics ... today announced a,collaboration to advance the discovery of ... of the agreement, Raven will license its proprietary,whole ...
Cached Biology Technology:Prometic to present at the American Chemical Society 2Prometic to present at the American Chemical Society 3Prometic to present at the American Chemical Society 4WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering 2Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies 2
(Date:10/14/2014)... DURHAM, N.C. – Like discriminating thieves, prostate cancer tumors ... in the body. But such avarice may be a ... found a way to kill prostate cancer cells by ... that selectively destroys the diseased cells brimming with the ... which uses two drugs already commercially available for other ...
(Date:10/14/2014)... is how to produce enough food to feed the ... Agriculture Organization of the United Nations predicts that food ... to feed a growing global population, and plants are ... production. Plants—grains, cereals, fruits, vegetables, and more—feed humans ... must tap into our knowledge of how plants work ...
(Date:10/14/2014)... A team of scientists led by researchers at ... the University of Miami Miller School of Medicine ... genetic pathway underlying bipolar (manic depressive) disorder, a ... treating bipolar affective disorder, as well as depression ... findings, published online this week in Nature ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... the University Hospital and the Center for Applied Medical ... an article in Nature Cancer Reviews , one ... cancer studies. The article, written by Ignacio Melero and ... States and Great Britain, addresses the use of a ...
... This week's BMJ investigates a bitter row over a ... scrutiny once again. , The dispute has pitted a ... Cha, a fertility specialist and one of the most ... writes journalist Jonathan Gornall. It is also threatening to ...
... are obese don’t really know they are overweight, researchers have ... published by Cell Press. These findings in obese mice show ... critical fat hormone—causing a cascade of events that keeps energy ... metabolic pathway remains ready to respond. , “Obesity is not ...
Cached Biology News:Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies 2Row over study puts Korea's scientific community under scrutiny again 2In obesity, brain becomes 'unaware' of fat 2In obesity, brain becomes 'unaware' of fat 3
... system from Molecular Devices provides precise dispensing ... The system handles a variety of plate ... and 1536-welland is the first to handle ... optimized to dispense from four different channels ...
... ProteinPilot Software enables you to ... Now you can distinguish protein isoforms, ... You can also visualize peptide-protein associations ... ideal for protein identification and relative ...
... ( Abpromise for all tested ... Synthetic peptide: VEEESFGPQPISRLE conjugated to KLH, ... 15-29 of Human Rad51 ... Swiss Protein ID: ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
Biology Products: